Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NQO1 | P15559 | 1/20 | 0.37 |
| ▸ | SCN9A | Q15858 | 8/20 | 0.36 |
| ▸ | SCN7A | Q01118 | 2/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.33 |
| ▸ | SYK | P43405 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | BLM | P54132 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1078194 | 0.72 | RAF1 (0.40) | ALDH1A1MAPTKDM4E | |
| SCHEMBL3393922 | 0.70 | MEN1 (0.47) | KCNH2ALDH1A1LMNA | |
| SCHEMBL1078190 | 0.70 | EPHX2 (0.34) | ALDH1A1MAPTBLMKDM4E | |
| SCHEMBL21683027 | 0.69 | HSD11B1 (0.41) | ALDH1A1LMNAHSD17B10 | |
| SCHEMBL18285758 | 0.68 | ALDH1A1 (0.33) | ALDH1A1MAPTBLMLMNAKDM4E | |
| SCHEMBL18285754 | 0.68 | ALDH1A1 (0.33) | ALDH1A1MAPTBLMLMNAKDM4E | |
| SCHEMBL15411209 | 0.67 | SMN1; SMN2 (0.37) | ALDH1A1MAPTALOX15HSD17B10 | |
| SCHEMBL23277677 | 0.66 | — | — | |
| SCHEMBL3391147 | 0.66 | HSD11B1 (0.44) | ALDH1A1LMNA | |
| SCHEMBL23277680 | 0.65 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060264460-A1 | 3-Cyanoquinoline inhibitors of Tpl2 kinase and methods of making and using the same | WYETH (US) | 2006-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060264460-A1 | 3-Cyanoquinoline inhibitors of Tpl2 kinase and methods of making and using the same | TNNI3K, CSNK1A1L, CDKL1 | NQO1 1057/4885SCN9A 4474/4885SCN7A 2375/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.